|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Geller DS and Gorlick R: Osteosarcoma: A
review of diagnosis, management, and treatment strategies. Clin Adv
Hematol Oncol. 8:705–718. 2010.PubMed/NCBI
|
|
3
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: State of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferrari S and Palmerini E: Adjuvant and
neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr
Opin Oncol. 19:341–346. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nouri H, Ben Maitigue M, Abid L, Nouri N,
Abdelkader A, Bouaziz M and Mestiri M: Surface osteosarcoma:
Clinical features and therapeutic implications. J Bone Oncol.
4:115–123. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan ML, Choong PF and Dass CR:
Osteosarcoma: Conventional treatment vs. gene therapy. Cancer Biol
Ther. 8:106–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hammond SM: An overview of microRNAs. Adv
Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yates LA, Norbury CJ and Gilbert RJ: The
long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tahara H, Kay MA, Yasui W and Tahara E:
MicroRNAs in cancer: the 22nd hiroshima cancer seminar/the 4th
Japanese Association for RNA interference joint international
symposium, 30 August 2012, Grand Prince Hotel Hiroshima. Jpn J Clin
Oncol. 43:579–582. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: microRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang X, Lin Y, Peng L, Sun R, Gong X, Du J
and Zhang X: MicroRNA-103 promotes proliferation and inhibits
apoptosis in spinal osteosarcoma cells by targeting p57. Oncol Res.
26:933–940. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xiao Y, Zhao Q, Du B, Chen HY and Zhou DZ:
MicroRNA-187 inhibits growth and metastasis of osteosarcoma by
downregulating S100A4. Cancer Invest. 36:1–9. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu Y, Chu H, Zhou Y, Wang J, Dong C and
Yin R: miR-365 functions as a tumor suppressor by directly
targeting CYR61 in osteosarcoma. Biomed Pharmacother. 98:531–537.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tong F, Ying Y, Pan H, Zhao W, Li H and
Zhan X: MicroRNA-466 (miR-466) functions as a tumor suppressor and
prognostic factor in colorectal cancer (CRC). Bosn J Basic Med Sci.
18:252–259. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Colden M, Dar AA, Saini S, Dahiya PV,
Shahryari V, Yamamura S, Tanaka Y, Stein G, Dahiya R and Majid S:
MicroRNA-466 inhibits tumor growth and bone metastasis in prostate
cancer by direct regulation of osteogenic transcription factor
RUNX2. Cell Death Dis. 8:e25722017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou LL, Shen Y, Gong JM, Sun P and Sheng
JH: MicroRNA-466 with tumor markers for cervical cancer screening.
Oncotarget. 8:70821–70827. 2017.PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhi X, Wu K, Yu D, Wang Y, Yu Y, Yan P and
Lv G: MicroRNA-494 inhibits proliferation and metastasis of
osteosarcoma through repressing insulin receptor substrate-1. Am J
Transl Res. 8:3439–3447. 2016.PubMed/NCBI
|
|
21
|
Ell B and Kang Y: MicroRNAs as regulators
of bone homeostasis and bone metastasis. Bonekey Rep. 3:5492014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kafchinski LA and Jones KB: MicroRNAs in
osteosarcomagenesis. Adv Exp Med Biol. 804:119–127. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim YH, Goh TS, Lee CS, Oh SO, Kim JI,
Jeung SH and Pak K: Prognostic value of microRNAs in osteosarcoma:
A meta-analysis. Oncotarget. 8:8726–8737. 2017.PubMed/NCBI
|
|
24
|
Porter HA, Perry A, Kingsley C, Tran NL
and Keegan AD: IRS1 is highly expressed in localized breast tumors
and regulates the sensitivity of breast cancer cells to
chemotherapy, while IRS2 is highly expressed in invasive breast
tumors. Cancer Lett. 338:239–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lai YY, Shen F, Cai WS, Chen JW, Feng JH,
Cao J, Xiao HQ, Zhu GH and Xu B: MiR-384 regulated IRS1 expression
and suppressed cell proliferation of human hepatocellular
carcinoma. Tumour Biol. 37:14165–14171. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Esposito DL, Aru F, Lattanzio R, Morgano
A, Abbondanza M, Malekzadeh R, Bishehsari F, Valanzano R, Russo A,
Piantelli M, et al: The insulin receptor substrate 1 (IRS1) in
intestinal epithelial differentiation and in colorectal cancer.
PLoS One. 7:e361902012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zheng H, Zhang F and Lin X, Huang C, Zhang
Y, Li Y, Lin J, Chen W and Lin X: MicroRNA-1225-5p inhibits
proliferation and metastasis of gastric carcinoma through
repressing insulin receptor substrate-1 and activation of β-catenin
signaling. Oncotarget. 7:4647–4663. 2016.PubMed/NCBI
|
|
28
|
Cao M, Li Y, Lu H, Meng Q, Wang L, Cai L
and Dong X: MiR-23a-mediated migration/invasion is rescued by its
target, IRS-1, in non-small cell lung cancer cells. J Cancer Res
Clin Oncol. 140:1661–1670. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Y, Zhang X, Zou C, Kung HF, Lin MC,
Dress A, Wardle F, Jiang BH and Lai L: miR-195 inhibits tumor
growth and angiogenesis through modulating IRS1 in breast cancer.
Biomed Pharmacother. 80:95–101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Y, Hu C, Cheng J, Chen B, Ke Q, Lv Z,
Wu J and Zhou Y: MicroRNA-145 suppresses hepatocellular carcinoma
by targeting IRS1 and its downstream Akt signaling. Biochem Biophys
Res Commun. 446:1255–1260. 2014. View Article : Google Scholar : PubMed/NCBI
|
